![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Telaprevir, Peginterferon and Ribavirin Combination Therapy for Chronic HCV Genotype 1 in HCV/HIV Co-infected Patients: Early Response and Viral Resistance
|
|
|
Reported by Jules Levin
CROI 2013 March 3-6 Atlanta
Kenneth E. Sherman,1 Doug J. Bartels,2 Mohammad Bsharat,2 Raymond A. Rubin,2 Tara L. Kieffer,2 Mark S. Sulkowski3
1University of Cincinnati College of Medicine, Cincinnati, OH, USA; 2Vertex Pharmaceuticals Incorporated, Cambridge, MA, USA; 3Johns Hopkins University School of Medicine, Baltimore, MD, USA
![CROI1.gif](../images/030913/030913-5/CROI1.gif)
![CROI2.gif](../images/030913/030913-5/CROI2.gif)
![CROI3.gif](../images/030913/030913-5/CROI3.gif)
![CROI4.gif](../images/030913/030913-5/CROI4.gif)
![CROI5.gif](../images/030913/030913-5/CROI5.gif)
![CROI6.gif](../images/030913/030913-5/CROI6.gif)
![CROI7.gif](../images/030913/030913-5/CROI7.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|